Select a Region

North America

Newscenter

Browsing Archive: AMLAML | EVERSANA

EVERSANA

Posted on 2 月 1, 20232/1/23

Systematic Literature Reviews (SLRS) of Economic Evaluations and Health Utility Studies of AML Treatments for Adults Receiving High Intensity Induction Therapy, with or without Maintenance Therapy

EVERSANA

Posted on 2 月 1, 20232/1/23

Systematic Literature Review of the Efficacy and Safety of Maintenance Therapies for Adults with Acute Myeloid Leukemia in Complete Remission who are Ineligible for Hematopoetic Stem Cell Transplant

EVERSANA

Posted on 2 月 1, 20232/1/23

European Guidelines and Real-World Evidence of Maintenance Treatments for Adults with Acute Myeloid Leukemia in First Complete Remission.

EVERSANA

Posted on 2 月 1, 20232/1/23

Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy.

AML